← Back to home

To assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS monoclonal antibodies in HIV-negative women

Clinical trials for To assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS monoclonal antibodies in HIV-negative women explained in plain language.

Never miss a new study

Get alerted when new To assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS monoclonal antibodies in HIV-negative women trials appear

Sign up with your email to follow new studies for To assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS monoclonal antibodies in HIV-negative women, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

Lab-Made antibodies put to the test as HIV prevention for women

Prevention Completed

Researchers are testing two lab-made antibodies, CAP256V2LS and VRC07-523LS, given as shots under the skin to young women who do not have HIV. The phase II trial enrolls about 990 women aged 18 to 30 in Zambia and nearby countries. It measures whether the shots cause serious reac…

Matched conditions: TO ASSESS EXTENDED SAFETY AND TOLERABILITY OF SUBCUTANEOUS CAP256V2LS AND VRC07-523LS MONOCLONAL ANTIBODIES IN HIV-NEGATIVE WOMEN

Phase 2 • Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Prevention

Last updated Sep 11, 2026 00:00 UTC

To assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS monoclonal antibodies in HIV-negative women

Get alerted when new To assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS monoclonal antibodies in HIV-negative women trials appear

Lab-Made antibodies put to the test as HIV prevention for women